Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women

Jennifer W. Bea, Sylvia Wassertheil-Smoller, Betsy C. Wertheim, Yann Klimentidis, Zhao Chen, Oleg Zaslavsky, Todd M. Manini, Catherine R. Womack, Candyce H. Kroenke, Andrea Z. Lacroix, Cynthia A. Thomson

Research output: Contribution to journalArticle

Abstract

Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (n=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., p=0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.

Original languageEnglish (US)
Article number8491092
JournalJournal of Aging Research
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Independent Living
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Linear Models
Hypertension
Photon Absorptiometry
Women's Health
Body Composition
Skeletal Muscle
Demography

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Cite this

Bea, J. W., Wassertheil-Smoller, S., Wertheim, B. C., Klimentidis, Y., Chen, Z., Zaslavsky, O., ... Thomson, C. A. (2018). Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women. Journal of Aging Research, 2018, [8491092]. https://doi.org/10.1155/2018/8491092

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women. / Bea, Jennifer W.; Wassertheil-Smoller, Sylvia; Wertheim, Betsy C.; Klimentidis, Yann; Chen, Zhao; Zaslavsky, Oleg; Manini, Todd M.; Womack, Catherine R.; Kroenke, Candyce H.; Lacroix, Andrea Z.; Thomson, Cynthia A.

In: Journal of Aging Research, Vol. 2018, 8491092, 01.01.2018.

Research output: Contribution to journalArticle

Bea, JW, Wassertheil-Smoller, S, Wertheim, BC, Klimentidis, Y, Chen, Z, Zaslavsky, O, Manini, TM, Womack, CR, Kroenke, CH, Lacroix, AZ & Thomson, CA 2018, 'Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women', Journal of Aging Research, vol. 2018, 8491092. https://doi.org/10.1155/2018/8491092
Bea, Jennifer W. ; Wassertheil-Smoller, Sylvia ; Wertheim, Betsy C. ; Klimentidis, Yann ; Chen, Zhao ; Zaslavsky, Oleg ; Manini, Todd M. ; Womack, Catherine R. ; Kroenke, Candyce H. ; Lacroix, Andrea Z. ; Thomson, Cynthia A. / Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women. In: Journal of Aging Research. 2018 ; Vol. 2018.
@article{b6520fdc8cb9428d8d4ed2bb31722a24,
title = "Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women",
abstract = "Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (n=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM ({\%}) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2{\%} versus 51.3{\%}, resp., p=0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.",
author = "Bea, {Jennifer W.} and Sylvia Wassertheil-Smoller and Wertheim, {Betsy C.} and Yann Klimentidis and Zhao Chen and Oleg Zaslavsky and Manini, {Todd M.} and Womack, {Catherine R.} and Kroenke, {Candyce H.} and Lacroix, {Andrea Z.} and Thomson, {Cynthia A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/8491092",
language = "English (US)",
volume = "2018",
journal = "Journal of Aging Research",
issn = "2090-2204",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women

AU - Bea, Jennifer W.

AU - Wassertheil-Smoller, Sylvia

AU - Wertheim, Betsy C.

AU - Klimentidis, Yann

AU - Chen, Zhao

AU - Zaslavsky, Oleg

AU - Manini, Todd M.

AU - Womack, Catherine R.

AU - Kroenke, Candyce H.

AU - Lacroix, Andrea Z.

AU - Thomson, Cynthia A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (n=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., p=0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.

AB - Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (n=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., p=0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.

UR - http://www.scopus.com/inward/record.url?scp=85043390044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043390044&partnerID=8YFLogxK

U2 - 10.1155/2018/8491092

DO - 10.1155/2018/8491092

M3 - Article

AN - SCOPUS:85043390044

VL - 2018

JO - Journal of Aging Research

JF - Journal of Aging Research

SN - 2090-2204

M1 - 8491092

ER -